Cutting-Edge Gene Therapies Epicrispr Biotechnologies is a pioneering biotechnology company focused on developing ultracompact therapies to modulate gene expression, leveraging the innovative CasMINI protein. This cutting-edge technology presents a unique selling point in the rapidly evolving biotech market.
Strategic Geographical Location Strategically situated in South San Francisco, a leading biotech hub, Epicrispr Biotechnologies benefits from close proximity to key industry players, fostering potential partnerships, collaborations, and synergies. This location advantage can be leveraged for expanding market reach and driving business growth.
Niche Product Differentiation With a focus on ultracompact gene therapies, Epicrispr Biotechnologies offers a niche product line that sets it apart from larger competitors. This unique specialization can be positioned as a distinct value proposition to target customers seeking innovative solutions in gene modulation.
Solid Revenue Potential Although currently in the revenue range of $0-10M, Epicrispr Biotechnologies exhibits strong growth potential in the biotechnology sector. By effectively showcasing the efficacy of their therapies and expanding their customer base, the company can capitalize on untapped sales opportunities to drive revenue growth.
Competitive Analysis Insights Comparative analysis with similar companies like Verve Therapeutics, Editas Medicine, and CRISPR Therapeutics reveals Epicrispr Biotechnologies' positioning in the market. Understanding competitor strategies, market gaps, and customer preferences can provide valuable insights for refining sales tactics and building a competitive edge.
295
$50M$100M
189$10M$50M
166$10M$50M
127$10M$50M
334$50M$100M
507$100M$1B
122$10M$50M
436$50M$100M
26| Epicrispr Biotechnologies Email Formats | Percentage |
| First.Last@epic-bio.com | 88% |
| Fir.Last@epic-bio.com | 6% |
| First.Middle@epic-bio.com | 3% |
| FLast@epic-bio.com | 3% |
Biotechnology ResearchCalifornia, United States11-50 Employees
Epicrispr Biotechnologies is a biotechnology company developing ultracompact therapies to modulate gene expression in vivo using the smallest known Cas protein, CasMINI.
Company Overview
Funding & FinancialsEpicrispr Biotechnologies's revenue is in the range of $10M
Funding & FinancialsEpicrispr Biotechnologies's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com